GlassScriptPhysician profile
Archana Aggarwal
NPI 1326024084
$2,944.67
in general payments reported to CMS, 2019-2025
24 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $500 · 2021: $245 · 2022: $652 · 2023: $486 · 2024: $462 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $18.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.77 |
| Education | $18.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $450.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $444.32 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $392.27 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $321.36 | 2022-2024 | Tavneos, Krystexxa, Epogen |
| Fresenius USA Marketing, INC. | $304.08 | 2019-2023 | Korsuva, Velphoro |
| Otsuka America Pharmaceutical, INC. | $213.10 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $135.01 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $110.26 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $93.76 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $76.36 | 2024-2025 | |
| Glaxosmithkline, LLC. | $64.70 | 2022-2023 | Benlysta, Jesduvroq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $59.27 | 2023-2025 | Jynarque |
| Vifor Pharma, INC. | $36.20 | 2022 | |
| Angiodynamics, INC. | $32.52 | 2019 | |
| Depuy Synthes Sales INC. | $28.05 | 2025 | Trufill |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.68 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.26 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.98 | 2025 | Acthar |
| Lilly USA, LLC | $22.72 | 2024 | Jardiance |
| Novo Nordisk INC | $19.80 | 2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.55 | 2023 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $18.31 | 2025 | Envarsus |
| Opko Pharmaceuticals, LLC | $18.20 | 2024 | Rayaldee |
| Ardelyx, INC. | $13.91 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.